AA1
MCID: ALP039
MIFTS: 29

Alopecia Areata 1 (AA1)

Categories: Immune diseases, Rare diseases, Skin diseases

Aliases & Classifications for Alopecia Areata 1

MalaCards integrated aliases for Alopecia Areata 1:

Name: Alopecia Areata 1 58 13 74
Aa1 58

Characteristics:

OMIM:

58
Inheritance:
multifactorial

Miscellaneous:
one of the most common autoimmune diseases
may coexist with autoimmune vitiligo or thyroiditis
alopecia may spontaneously regress, become chronic, or spread diffusely


HPO:

33
alopecia areata 1:
Inheritance multifactorial inheritance


Classifications:



External Ids:

OMIM 58 104000
MedGen 43 C1863094
UMLS 74 C1863094

Summaries for Alopecia Areata 1

OMIM : 58 Alopecia areata is a genetically determined, immune-mediated disorder of the hair follicle with an estimated lifetime risk of approximately 2%, making it one of the most common human autoimmune diseases. It shows a spectrum of severity that ranges from patchy localized hair loss on the scalp to the complete absence of hair everywhere on the body (Gilhar and Kalish, 2006). (104000)

MalaCards based summary : Alopecia Areata 1, also known as aa1, is related to alopecia areata and alopecia universalis congenita. An important gene associated with Alopecia Areata 1 is AA1 (Alopecia Areata 1). The drugs Caffeine and Tacrolimus have been mentioned in the context of this disorder. Affiliated tissues include lung, kidney and bone, and related phenotypes are autoimmunity and nail pits

Related Diseases for Alopecia Areata 1

Diseases in the Alopecia Areata family:

Alopecia Areata 1 Alopecia Areata 2

Diseases related to Alopecia Areata 1 via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 alopecia areata 11.3
2 alopecia universalis congenita 11.2
3 cone-rod dystrophy and hearing loss 2 11.1
4 alopecia areata 2 10.1

Symptoms & Phenotypes for Alopecia Areata 1

Human phenotypes related to Alopecia Areata 1:

33 (show all 6)
# Description HPO Frequency HPO Source Accession
1 autoimmunity 33 HP:0002960
2 nail pits 33 HP:0001803
3 alopecia universalis 33 HP:0002289
4 alopecia areata 33 HP:0002229
5 alopecia totalis 33 HP:0007418
6 trachyonychia 33 HP:0030804

Symptoms via clinical synopsis from OMIM:

58
Skin Nails Hair Nails:
nail pitting
trachyonychia (rough surfaced nails)

Skin Nails Hair Hair:
patchy round or oval hair loss (alopecia areata)
alopecia totalis (entire loss of scalp hair)
alopecia universalis (entire loss of all hair on body)
peribulbar lymphocytic infiltrate (on scalp biopsy)

Clinical features from OMIM:

104000

Drugs & Therapeutics for Alopecia Areata 1

Drugs for Alopecia Areata 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 77)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Caffeine Approved Phase 4 58-08-2 2519
2
Tacrolimus Approved, Investigational Phase 4 104987-11-3 6473866 445643 439492
3 Immunosuppressive Agents Phase 4,Not Applicable
4 Immunologic Factors Phase 4,Not Applicable
5 Calcineurin Inhibitors Phase 4,Not Applicable
6 Phosphodiesterase Inhibitors Phase 4,Phase 2
7 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1
8 Purinergic P1 Receptor Antagonists Phase 4
9 Central Nervous System Stimulants Phase 4
10
Benzocaine Approved, Investigational Phase 2, Phase 3 1994-09-7, 94-09-7 2337
11
tannic acid Approved Phase 2, Phase 3 1401-55-4
12
Budesonide Approved Phase 3,Phase 2 51333-22-3 5281004 63006
13
Fluticasone Approved, Experimental Phase 3 90566-53-3 62924
14 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1,Not Applicable
15 Autonomic Agents Phase 3,Phase 2,Phase 1,Not Applicable
16 Hormones Phase 3,Phase 2,Phase 1,Not Applicable
17 Hormone Antagonists Phase 3,Phase 2,Phase 1,Not Applicable
18 glucocorticoids Phase 3,Phase 2,Phase 1,Not Applicable
19 Anti-Inflammatory Agents Phase 3,Phase 2,Phase 1,Not Applicable
20 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2,Phase 1,Not Applicable
21 Dermatologic Agents Phase 3,Not Applicable
22 Adrenergic beta-Agonists Phase 3,Phase 1
23 Bronchodilator Agents Phase 3,Phase 2,Phase 1
24 Anti-Asthmatic Agents Phase 3,Phase 2,Phase 1
25 Adrenergic beta-2 Receptor Agonists Phase 3,Phase 1
26 Adrenergic Agonists Phase 3,Phase 1
27 Adrenergic Agents Phase 3,Phase 1
28 Anticonvulsants Phase 3,Phase 1,Phase 2
29 Budesonide, Formoterol Fumarate Drug Combination Phase 3
30
Beclomethasone Phase 3,Phase 1 4419-39-0 20469
31 Respiratory System Agents Phase 3,Phase 2,Phase 1
32 Bromides Phase 3,Phase 1,Phase 2
33
Glycopyrrolate Phase 3,Phase 2,Phase 1 596-51-0 3494
34 Muscarinic Antagonists Phase 3,Phase 2,Phase 1
35 Cholinergic Antagonists Phase 3,Phase 2,Phase 1
36 Anesthetics Phase 3,Phase 2,Phase 1
37 Adjuvants, Anesthesia Phase 3,Phase 2,Phase 1
38 Cholinergic Agents Phase 3,Phase 2,Phase 1
39 Formoterol Fumarate Phase 3,Phase 1
40 Anti-Allergic Agents Phase 3
41 Parasympatholytics Phase 3
42 Tiotropium Bromide Phase 3 136310-93-5
43 Poractant alfa Approved Phase 2 129069-19-8
44 Phosphodiesterase 4 Inhibitors Phase 2
45 Pulmonary Surfactants Phase 2
46
Ethanol Approved Phase 1 64-17-5 702
47
Cimetidine Approved, Investigational Phase 1 51481-61-9 2756
48
Histamine Approved, Investigational Phase 1 51-45-6 774
49 Gastrointestinal Agents Phase 1,Not Applicable
50 Histamine H2 Antagonists Phase 1

Interventional clinical trials:

(show all 32)
# Name Status NCT ID Phase Drugs
1 The Effects of Caffeine and L-theanine Both Alone and in Combination on Cerebral Blood Flow, Cognition and Mood Completed NCT00981955 Phase 4
2 Pharmacokinetic Study of ENVARSUS in Adult De-novo Kidney Transplant Patients Completed NCT02500212 Phase 4 ENVARSUS®;ADVAGRAF®
3 Multicentre, Open Label, Randomized, Two-arm, Parallel-group Study to Assess Efficacy and Safety of ENVARSUS® Compared With Tacrolimus Used as Per Current Clinical Practice in the Initial Maintenance Setting in de Novo Kidney Transplant Patients Completed NCT02432833 Phase 4 ENVARSUS®;PROGRAF®;ADVAGRAF®
4 A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata Recruiting NCT03570749 Phase 2, Phase 3 Baricitinib;Placebo
5 Active Controlled Trial of CHF5993 Pressurized Metered-dose Inhaler ( pMDI) vs Symbicort®Turbuhaler® in Patients With Chronic Obstructive Pulmonary Disease ( COPD) Recruiting NCT03197818 Phase 3 CHF 5993 100/6/12.5 µg;160 µg budesonide + 4.5 µg formoterol fumarate
6 Functional Respiratory Imaging Study (FRI) Completed NCT03268226 Phase 3 Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium
7 2-arm Parallel Group Study of Fixed Combination of CHF 5993 vs Ultibro® in COPD Patients Completed NCT02579850 Phase 3 CHF 5993 + Ultibro matched placebo;Ultibro + CHF 5993 matched placebo
8 Non Inferiority of Fixed Combination of Beclomethasone Dipropionate (BDP) + Formoterol Fumarate (FF) + Glycopyrronium Bromide (GB) Versus Combination of Fluticasone Furoate (FlF)/Vilanterol (VI) + Tiotropium Bromide in Chronic Obstructive Pulmonary Disease (COPD) Completed NCT02467452 Phase 3 BDP/FF/GB;FlF/VI + Tiotropium
9 Itacitinib for Low Risk GVHD Recruiting NCT03846479 Phase 2 Itacitinib
10 A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Dose in Healthy Volunteers, Repeat Doses in Asthmatic Patients and of Single Dose in COPD Patients of CHF6366 Completed NCT03378648 Phase 1, Phase 2 CHF6366;Placebo CHF6366;umeclidinium bromide and vilanterol trifenatate
11 Pharmacodynamics, Pharmacokinetics and Safety of Two Doses of CHF6001 DPI in Subjects With Moderate, Severe COPD Completed NCT03004417 Phase 2 CHF 6001 Dose1;CHF 6001 Dose2
12 A 24-wk Dose Ranging Study to Evaluate the Efficacy and Safety of 4 Doses of a New PDE4 Inhibitor in Patients With COPD Completed NCT02986321 Phase 2 CHF6001;Budesonide;Placebo
13 A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Doses of CHF6297 in Healthy Subjects and Patients With COPD Terminated NCT02815488 Phase 1, Phase 2 CHF6297 (Part 1 - SAD);Placebo (Part 1 - SAD);CHF6297 (Part 2 - MAD);Placebo (Part 2 - MAD);CHF6297 (Part 3);Placebo (Part 3);CHF6297 (Part 4);Placebo (Part 4)
14 Study to Evaluate Efficacy/Safety of 4 Doses of CHF5259 Via Dry Powder Inhaler (DPI) in Patients With COPD Completed NCT02680197 Phase 2 CHF5259 or Placebo administration
15 A Double Blind, Randomized, Controlled Study to Compare CHF 5633 (Synthetic Surfactant) and Poractant Alfa in RDS Completed NCT02452476 Phase 2 CHF5633;Poractant alfa
16 Efficacy and Safety of Glycopyrrolate Bromide of COPD Patients Completed NCT02189577 Phase 2 CHF 5259;Placebo
17 Motivational and Cognitive Intervention for College Drinkers Unknown status NCT01204229 Phase 1
18 PK Linearity and Steady State PK of CHF 6532 in Healthy Subjects Not yet recruiting NCT03942666 Phase 1 Treatment A;Treatment B;Treatment C;Treatment D;Treatment E;Treatment F
19 Lung Deposition of TRIMBOW® pMDI in Healthy Volunteers, Asthmatic and COPD Patients Recruiting NCT03795350 Phase 1 Beclometasone dipropionate Formoterol Fumarate Glycopyrronium Bromide
20 A Study to Investigate Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of CHF6333 in Healthy Subjects Completed NCT03056326 Phase 1 CHF6333 (Part 1 - SAD);Placebo (Part 1 - SAD);CHF6333 (Part 2 - MAD);Placebo (Part 2 - MAD)
21 Pharmacokinetic Interaction and the Safety of Inhaled CHF5259 and CHF6001 Completed NCT03004495 Phase 1 CHF5259 and CHF6001;CHF5259 + placebo;CHF6001 + placebo
22 Lung Deposition of Beclometasone Dipropionate/Formoterol Fumarate/Glycopyrronium Bromide Administered Via pMDI in Healthy, Asthmatic and COPD Patients Completed NCT02975843 Phase 1 Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium
23 A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Inhaled CHF6001 Completed NCT02386761 Phase 1 Single Ascending Dose (SAD);Multiple Ascending Dose (MAD)
24 Drug-drug Interaction Study of CHF5993 With Cimetidine Completed NCT02287272 Phase 1 CHF 5993 pMDI;Cimetidine plus CHF5993 pMDI
25 Study to Investigate the Pharmacokinetics of CHF 6001 DPI Administered Via Nexthaler® Device or the Capsule for Oral Inhalation Via Aerolizer® Device Completed NCT02119247 Phase 1
26 Pharmacokinetics of CHF 5993 pMDI With and Without Spacer in COPD Patients Completed NCT02119234 Phase 1 Beclometasone/formoterol/glycopyrrolate;Placebo
27 A Study to Investigate the Pharmacokinetics, Safety and Tolerability of CHF 5993 pMDI in Subjects With Renal Impairment. Completed NCT02040597 Phase 1 Beclometasone/Formoterol/Glycopyrrolate
28 Study of Allogeneic Bone Marrow and T-Cell Depleted, CD34+ Peripheral Blood Stem Cell Transplantation in Patients With Aplastic Anemia Unknown status NCT00017654 Not Applicable anti-thymocyte globulin;cyclophosphamide;cyclosporine;methylprednisolone
29 Effect of the Use of an add-on Device Connected to a Smartphone App on Difficult-to-treat Asthmatic Patient's Adherence Not yet recruiting NCT03951714 Not Applicable
30 Outcomes and User Acceptance of the IntelliVue Alarm Advisor Software (Europe) Completed NCT03182452
31 Pediatric Arm of DZL All Age Asthma Cohort Recruiting NCT02496468
32 Functional Dyspepsia Microbiome Study Completed NCT02340312

Search NIH Clinical Center for Alopecia Areata 1

Genetic Tests for Alopecia Areata 1

Anatomical Context for Alopecia Areata 1

MalaCards organs/tissues related to Alopecia Areata 1:

42
Lung, Kidney, Bone, Skin, Thyroid, Bone Marrow, T Cells

Publications for Alopecia Areata 1

Articles related to Alopecia Areata 1:

(show all 14)
# Title Authors Year
1
Draft Genome Sequences of Extended-Spectrum-Beta-Lactamase-Producing Morganella morganii Strains AA1 and AV1, Isolated from a Freshwater Lake and Eicchorniacrassipes Roots. ( 28619802 )
2017
2
Comparison of the dark and light-induced toxicity of thio and seleno analogues of the thiopyrylium dye AA1. ( 15110840 )
2004
3
Superior signal-to-noise ratio of a new AA1 sequence for random-modulation continuous-wave lidar. ( 15352345 )
2004
4
Characterisation of the genes encoding Aa1 isoforms from the scorpion Androctonus australis. ( 12467669 )
2003
5
In vitro photodynamic properties of chalcogenopyrylium analogues of the thiopyrylium antitumor agent AA1. ( 12408723 )
2002
6
A selenopyrylium photosensitizer for photodynamic therapy related in structure to the antitumor agent AA1 with potent in vivo activity and no long-term skin photosensitization. ( 11087573 )
2000
7
2,4,6-triarylchalcogenopyrylium dyes related in structure to the antitumor agent AA1 as in vitro sensitizers for the photodynamic therapy of cancer. ( 10508442 )
1999
8
Bond champ. Sisters of Mercy is 1st not-for-profit with Moody's Aa1 rating. ( 10168834 )
1997
9
AA1, a newly synthesized monovalent lipophilic cation, expresses potent in vivo antitumor activity. ( 8137249 )
1994
10
Features of a Clostridium, strain CV-AA1, an obligatory anaerobic bacterium producing acetic acid from methanol. ( 7149697 )
1982
11
Estimation by radioimmunoassay of VH determinants (Aa1) associated with rabbit T lymphocytes. ( 68882 )
1977
12
The complete amino acid sequence of an amyloid fibril protein AA1 of unusual size (64 residues). ( 1259755 )
1976
13
Comparison of AA1 allotypic specificity carried by rabbit IgG and IgM. ( 4182114 )
1969
14
Rabbit lymphoid cells differentiated with respect to alpha-, gamma-, and mu- heavy polypeptide chains and to allotypic markers Aa1 and Aa2. ( 4160817 )
1966

Variations for Alopecia Areata 1

Expression for Alopecia Areata 1

Search GEO for disease gene expression data for Alopecia Areata 1.

Pathways for Alopecia Areata 1

GO Terms for Alopecia Areata 1

Sources for Alopecia Areata 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....